Pharma Partnering US: $66B Deal Surge, Lilly & Sun Lead

Key Takeaways

• Pharma Partnering Summit US 2026 is underway in San Diego, bringing together business development leaders.
• Pharma dealmaking has surged to $66 billion in valuation, doubling the previous year's figures.
• Sun Pharmaceuticals is set to acquire Organon for $11.75 billion, expanding its presence in women's health.
• Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, marking its sixth acquisition this year.

The Pharma Partnering Summit US 2026 is being held in San Diego, California, from April 29–30, 2026, gathering senior business development and licensing executives. This year's summit takes place amidst a significant surge in pharmaceutical dealmaking activity, with the total valuation of deals approximately doubling compared to the previous year.

The Pharma Partnering Summit US event provides a venue for companies to explore collaborations and acquisitions. This year's event is particularly noteworthy given the increased level of investment and strategic realignment occurring within the pharmaceutical industry.

Pharma Dealmaking Surge

Pharma dealmaking has reached approximately $66 billion in valuation in 2026, a substantial increase from the previous year. This surge reflects a period of intense investment and strategic repositioning as companies seek to bolster their pipelines and market presence.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for biotech. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Major Acquisitions

Several major acquisitions have been announced recently, highlighting the industry's appetite for growth through strategic combinations:

• Sun Pharmaceuticals is acquiring Organon (brand name not applicable) for $11.75 billion, a move that will significantly enhance its portfolio in women's health.
• Eli Lilly is acquiring Ajax Therapeutics (brand name not applicable) for up to $2.3 billion. This acquisition marks Lilly's sixth of the year, underscoring its aggressive growth strategy.
• Earlier in April, Merck finalized its $6.7 billion acquisition of Terns Pharma (brand name not applicable) and its $9.2 billion acquisition of Cidara Therapeutics (brand name not applicable).

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Key Partnership Announcements (Q1 2026)

In addition to acquisitions, several key partnerships have been announced in the first quarter of 2026:

• OPKO Health & Entera Bio: Expanded their collaboration on an oral long-acting PTH (parathyroid hormone variant) tablet for hypoparathyroidism. The collaboration features 50/50 ownership and cost-sharing, with an IND filing planned for late 2026 following positive PK/PD data from December 2025.
• Santhera Pharmaceuticals & Nxera Pharma: Entered into an exclusive license agreement in January 2026 for AGAMREE (vamorolone) in Japan/APAC, valued at up to $215 million plus royalties, including $40 million upfront ($30 million cash + $10 million equity).
• Santhera & Catalyst Pharmaceuticals: The AGAMREE (vamorolone) North America partnership generated $117 million in US sales in 2025, resulting in a $12.5 million milestone payment to Santhera. The 2026 sales guidance is projected at $140-150 million.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for biotech pricing, access, and launch sequencing.

Market & Investor Implications

The surge in pharma dealmaking and strategic partnerships reflects a dynamic market environment. Investors are closely watching these developments, as they can significantly impact company valuations and future growth prospects. Regulatory developments also continue to play a crucial role in shaping industry strategy.

IntelligenceStrategic Takeaways▾

Pharma Partnering Summit US 2026 is underway in San Diego, bringing together business development leaders. Pharma dealmaking has surged to $66 billion in valuation, doubling the previous year's figures. Sun Pharmaceuticals is set to acquire Organon for $11.75 billion, expanding its presence in women's health.

What to Watch Next

The industry will be closely monitoring the integration of acquired companies and the progress of partnered programs. Upcoming data readouts and regulatory decisions will also be key catalysts for market activity.

Frequently Asked Questions

1. What is the Pharma Partnering Summit US?

   The Pharma Partnering Summit US is an annual event that brings together senior business development and licensing leaders in the pharmaceutical industry to facilitate dealmaking and strategic collaborations.

2. Why is there a surge in pharma dealmaking?

   The surge in pharma dealmaking reflects a strategic realignment within the industry, driven by the need to bolster pipelines, expand market presence, and capitalize on emerging therapeutic areas.

3. What are some of the key acquisitions announced recently?

   Key acquisitions include Sun Pharmaceuticals acquiring Organon for $11.75 billion and Eli Lilly acquiring Ajax Therapeutics for up to $2.3 billion. Merck also completed its acquisitions of Terns Pharma and Cidara Therapeutics earlier in April.

4. What is AGAMREE (vamorolone)?

   AGAMREE (vamorolone) is a drug commercialized by Santhera and Catalyst Pharmaceuticals through a North American partnership that generated $117 million in sales in 2025.

References

1. Pharma Partnering Summit US 2026 Returns to San Diego to Connect Global BDL Leaders
2. Drugmakers Race to Lock Up Assets in $66B Deal Blitz
3. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
4. Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

Related coverage

• AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
• Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
• AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands